Skip to Content

Posts tagged with "Academia (vs. Industry)"

  • Academia (vs. Industry)

    Advice for Academic Entrepreneurs

    Since I’ve mentioned a recent book on academic drug discovery, I also wanted to highlight this article at Nature Biotechnology on university tech transfer offices (TTOs). The authors, mostly from a list of high-profile research universities (Oxford, Stanford, UCSF, University College London, Harvard et al.) and part of the Oxbridge Biotech Ro… Read More
  • Academia (vs. Industry)

    Drug Development for Academics

    I have a book review out in Nature Chemical Biology of A Practical Guide to Drug Development in Academia. As you’ll see, I liked it, finding it a very useful guide to real-world drug discovery for people who are interested in what they’d need to do to get into it. Here’s a quote that some… Read More
  • Academia (vs. Industry)

    What Industry Would Like to Hear About

    Here’s a good paper from Phil Baran and co-workers in Accounts of Chemical Research on the relationship between industrial and academic research. It’s illustrated with examples from his own work, such as the ingenol synthesis, and with new synthetic methods discovered in collaboration with Bristol-Myers Squibb, Pfizer, Eisai, and Sigma- Read More
  • Academia (vs. Industry)

    Drug Industry Trials vs. NIH-Funded Ones: Who Reports on Time?

    This article at NEJM is looking at how well clinical trial results are made public, which has been a big topic over the last few years. Let me say up front that the results are quite interesting, and that some news outlets appear to be misreporting them. Since 2007, it’s been required by law that… Read More
  • Academia (vs. Industry)

    The State of US Medical Research

    Here’s a look at the state of medical research in the US versus other developed countries (open-access article at JAMA). Some things to note from that chart: (1) research funding has been pretty flat the last few years, with the only exception being the stimulus-package burst of cash. (2) The share of the total put… Read More
  • Academia (vs. Industry)

    More Odd Compounds

    When you look into the literature on small-molecule agents for really tricky targets, something stands out to medicinal chemists immediately: the structures start to get strange. Examples of this sort of thing are beyond counting, but this recent paper will serve as well as any. It’s from a large multicenter academic team, and proposes severa… Read More
  • Academia (vs. Industry)

    Ambition From Recursion

    Here’s one to put in the “hubris” file – we’ll have to wait to see whether or not it’s followed by the traditional divine retribution. According to Drug Discovery & Development (note: corrected source), startup Recursion Pharmaceuticals, out of the University of Utah, states that they’re going to devel… Read More
  • Academia (vs. Industry)

    Postdoctoral Life (AKA What Shortage?)

    . . .is not very pleasant, according to this report. It never has been, but it’s not getting any better. This should sound familiar to many people: it is notoriously difficult to determine how many postdoctoral scholars there are, let alone what kind of training they are or should be receiving. The National Institutes of… Read More
  • Academia (vs. Industry)

    Francis Collins Knows Why We Don’t Have An Ebola Vaccine

    NIH Director Francis Collins has been saying that if only the agency’s budget hadn’t been cut, that we would already have an Ebola vaccine. He tried this line out during recent Congressional testimony, and apparently liked it enough that he expanded on it in an article for the Huffington Post. Collins’ statements have been fodder… Read More
  • Academia (vs. Industry)

    Different Screening, Different Thermodynamics?

    Chris Lipinski and the folks at Collaborative Drug Discovery send word of an interesting webinar that will take place this coming Wednesday (October 22nd) at 2 PM EST. It’s on enthalpic and entropic trends in ligand binding, and how various screening and discovery techniques might bias these significantly. Here’s the registration page i… Read More
...234...